Concepedia

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Dik J. Kwekkeboom, Willem H. Bakker, Boen L.R. Kam, Jaap J.M. Teunissen, P.P.M. Kooij, Wouter W. de Herder, Richard A. Feelders, Casper H.J. van Eijck, Marion de Jong, A. Srinivasan,

European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 422 citations · 14 references

DOIFull text

Open access

Concepts

References

14

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations

, , +15

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 1.1K citations

, , +15

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 471 citations

, , +3

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Roelf Valkema, Marion de Jong, Willem H. Bakker et al. · Seminars in Nuclear Medicine · 2002 · 433 citations

, , +14

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

Christian Waldherr, Misha Pless, Helmut R. Maëcke et al. · Annals of Oncology · 2001 · 394 citations

, , +11